• KX2-391 Analogues and Oncogenic Kinase SAR

  2026-09-30

  This 2022 Frontiers in Oncology study used scaffold hopping to test whether KX2-391 analogues retained Src inhibition and tubulin disruption or acquired different kinase activities. The lead analogue 4e preferentially affected leukemia models and strongly altered ERK1/2 and c-Jun kinase signaling without depending on either parental mechanism, demonstrating why analogue SAR requires broad functional profiling.

• Exendin-4: From cAMP Biology to Translation

  2026-09-30

  A mechanism-first perspective on Exendin-4 and Exenatide, linking GLP-1 receptor signaling, beta cell function research, metabolic phenotyping, and emerging yeast-expression strategies for more accessible type 2 diabetes research.

• BAY-826: Retinal Signaling for Translational Research

  2026-09-29

  BAY-826 offers a potent chemical perturbation strategy for testing angiopoietin-linked control of Müller cell signaling, PEDF production, and retinal neuron survival. This perspective connects pathway biology with assay design while separating established evidence from translational hypotheses.

• Pemetrexed as a Precision Probe in Mesothelioma

  2026-09-29

  Pemetrexed can be more than a cytotoxic control: its multi-target antifolate activity provides a mechanistic entry point for connecting folate stress, nucleotide depletion, replication vulnerability, and DNA-repair phenotypes. This thought-leadership guide translates evidence from malignant pleural mesothelioma research into practical assay design, biomarker strategy, and translational positioning.

• Bifendate Blocks Autophagy and Lipid Accumulation

  2026-09-28

  The reference study shows that bifendate inhibits autophagy at several mechanistically distinct stages, including autophagosome–lysosome fusion, lysosome acidification, and autophagic lysosome reformation. It also reduces oleic acid-induced lipid droplet accumulation, providing a more nuanced basis for interpreting bifendate in liver-disease and lipid-metabolism models.

• TH287 MTH1 Inhibitor for Cancer Radiosensitization

  2026-09-28

  TH287 provides a practical way to test whether blocking oxidized-nucleotide cleanup can amplify radiation-associated stress in cancer cells. A castration-resistant prostate cancer study highlights a schedule-sensitive effect: irradiation 12 hours after TH287 produced stronger responses than later schedules in PC-3 and DU-145 cells.

• Octanoic Acid-Rich Nutrition and Macrophage Balance in IBD

  2026-09-27

  This study reports that octanoic acid-rich enteral nutrition alleviated inflammatory bowel disease in an experimental model while shifting intestinal macrophage polarization through PPARγ/STAT-1/STAT-6 signaling. Its combination of nutritional intervention and pathway perturbations offers a mechanistic basis for further testing, but does not establish clinical efficacy or define a treatment dose.

• Dehydroabietic Acid in PPAR Metabolism Research

  2026-09-26

  Dehydroabietic acid offers a way to investigate dual PPAR-α/γ activation alongside lipid and insulin-response endpoints. This practical workflow emphasizes dose finding, solvent controls, receptor-specific validation, and careful separation of receptor signaling from nutrient-metabolism effects.

• pH-Sensitive Nanoparticles Against Breast Cancer Stem-Cell R

  2026-09-25

  The study evaluates a pH-responsive nanoparticle system combining schisandrin B (SchB) with an ATRA-grafted polymer to address multidrug resistance in breast cancer stem cells. Its in vitro findings link increased drug release under more acidic conditions with reduced P-glycoprotein expression, altered drug-efflux energy supply, and improved cytotoxic activity against the resistant cell model.

• Senolytic Targeting After Temozolomide in Glioblastoma

  2026-09-25

  Schwarzenbach and colleagues found that temozolomide-treated glioblastoma cells upregulated anti-apoptotic c-IAP2 and Bcl-2 as they entered senescence. In cell-line experiments, inhibiting these survival factors with BV6 and venetoclax increased cell death, supporting a sequential strategy to investigate senescent tumor-cell clearance after chemotherapy.

• BGJ398 Workflows for FGFR Signaling Research

  2026-09-24

  Use BGJ398 (NVP-BGJ398) to test whether FGFR1–3 kinase activity supports cancer-cell growth or developmental-tissue phenotypes. This guide pairs practical dose-finding and assay controls with the limits of applying an oncology tool to a developmental model.

• PPARγ Activation Rebalances Macrophages in DSS Colitis

  2026-09-24

  In cell and mouse models, the study links PPARγ activation to reduced STAT-1 signaling, increased STAT-6 signaling, and a shift in macrophage markers associated with less severe DSS-induced colitis. The findings support a testable pathway connecting macrophage polarization with intestinal inflammation, while leaving questions about causality, model scope, and clinical relevance open.

• Recombinant Mouse M-CSF, Tag Free for Macrophage Assays

  2026-09-23

  Use Recombinant Mouse M-CSF, Tag Free to build a consistent mouse macrophage platform for testing tumor–immune interactions and antigen presentation. This workflow connects macrophage preparation to a cholangiocarcinoma study of PDHA1 succinylation while distinguishing practical assay recommendations from the paper’s findings.

• Meropenem Workflows for Infection Research

  2026-09-23

  Build more informative infection assays with Meropenem by combining MIC testing, time-kill kinetics, resistance surveillance, and formulation controls. This workflow distinguishes broad antibacterial coverage from isolate-specific susceptibility and supports Gram-negative, Gram-positive, anaerobic, and septicemia treatment research without confusing preclinical findings with clinical guidance.

• WTAP–GLS Splicing Drives Ferroptosis Resistance in HCC

  2026-09-22

  The reference study identifies an EGFR–AKT–WTAP–GLS pathway that rewires glutamine metabolism and protects hepatocellular carcinoma cells from ferroptosis. Its central advance is linking WTAP phosphorylation and m6A-dependent alternative splicing to the preferential production of the GAC glutaminase isoform, providing a mechanistic basis for therapeutic strategies targeting metabolic plasticity.

8696 records 1/580 page Next 12345 下5页 Last page